lenvatinib + sorafenib

Lenvatinib + sorafenib is a combination of two oral small molecule multikinase inhibitors, each approved individually for the treatment of advanced hepatocellular carcinoma (HCC) and other cancers. Both drugs act as tyrosine kinase inhibitors (TKIs), targeting multiple receptor tyrosine kinases involved in tumor angiogenesis, growth, and progression. Lenvatinib inhibits vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. Sorafenib targets VEGFR2/3, PDGFRβ, RAF kinases, KIT, FLT-3, and RET. The combination has been explored in clinical settings but is not an established or approved regimen; both are more commonly used as monotherapies or in combination with other agents such as immunotherapies or transarterial chemoembolization (TACE). Their mechanisms overlap but also complement each other by inhibiting a broader spectrum of signaling pathways critical to tumor vascularization and proliferation[6][10][8].